PBAX
Income statement / Annual
Last year (2022), Phoenix Biotech Acquisition Corp.'s total revenue was $254,831.00,
and the percentage change from the previous year is not available.
In 2022, Phoenix Biotech Acquisition Corp.'s net income was -$667,736.00.
See Phoenix Biotech Acquisition Corp.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$254,831.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
| Gross Profit |
$254,831.00 |
$0.00 |
| Gross Profit Ratio |
1 |
0 |
| Research and Development
Expenses |
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$2.84 M
|
$431.50
|
| Selling & Marketing
Expenses |
$0.00
|
$251,274.00
|
| Selling, General &
Administrative Expenses |
$2.84 M
|
$251,705.00
|
| Other Expenses |
$64,050.00 |
-$80,320.00 |
| Operating Expenses |
$2.91 M |
$332,026.00 |
| Cost And Expenses |
$2.91 M |
$332,030.00 |
| Interest Income |
$2.84 M |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
-$5.67 M
|
$236,558.00
|
| EBITDA |
-$5.74 M
|
-$332,030.00
|
| EBITDA Ratio |
-22.53 |
0 |
| Operating Income Ratio
|
-0.27
|
0
|
| Total Other
Income/Expenses Net |
-$65,671.56
|
-$385.00
|
| Income Before Tax |
-$68,577.00 |
-$332,415.00 |
| Income Before Tax Ratio
|
-0.27
|
0
|
| Income Tax Expense |
$599,159.00 |
-$16,868.00 |
| Net Income |
-$667,736.00 |
-$315,547.00 |
| Net Income Ratio |
-2.62 |
0 |
| EPS |
-0.0373 |
-0.0137 |
| EPS Diluted |
-0.0373 |
-0.0137 |
| Weighted Average Shares
Out |
$17.90 M
|
$22.98 M
|
| Weighted Average Shares
Out Diluted |
$17.90 M
|
$22.98 M
|
| Link |
|
|
